Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
Earnings for Laurus Labs Limited (LAURUSLABS.NS)
Earnings in 2023 (TTM): $28 M
According to Laurus Labs Limited's latest financial reports the company's current earnings (TTM) are $28 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Laurus Labs Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $28 M | $19.02 M |
| 2022 | $131.38 M | $93.61 M |
| 2021 | $128.41 M | $98.04 M |
| 2020 | $154.15 M | $116.53 M |
| 2019 | $34.79 M | $30.24 M |
| 2018 | $14.19 M | $11.11 M |
| 2017 | $28.13 M | $19.86 M |
| 2016 | $27.87 M | $22.54 M |
| 2015 | $19.85 M | $15.72 M |
| 2014 | $7.89 M | $8.1 M |
| 2013 | $14.32 M | $11.52 M |
| 2012 | $10.2 M | $10.45 M |